Cytosorbents Total Liab vs Current Deferred Revenue Analysis

CTSO Stock

USD 0.98 0.01 1.03%

Cytosorbents Crp financial indicator trend analysis is way more than just evaluating Cytosorbents Crp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytosorbents Crp is a good investment. Please check the relationship between Cytosorbents Crp Total Liab and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Total Liab vs Current Deferred Revenue

Total Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytosorbents Crp Total Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Cytosorbents Crp's Total Liab and Current Deferred Revenue is 0.5. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Cytosorbents Crp, assuming nothing else is changed. The correlation between historical values of Cytosorbents Crp's Total Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Cytosorbents Crp are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Liab i.e., Cytosorbents Crp's Total Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.5

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Cytosorbents Crp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytosorbents Crp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.At this time, Cytosorbents Crp's Selling General Administrative is very stable compared to the past year. As of the 21st of May 2024, Issuance Of Capital Stock is likely to grow to about 17.5 M, while Tax Provision is likely to drop (854.4 K).

	2021	2022	2023	2024 (projected)
Other Operating Expenses	62.9M	60.9M	66.9M	70.2M
Total Revenue	40.1M	29.4M	36.3M	38.2M

Other Operating Expenses Total Revenue

Cytosorbents Crp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Non Current Assets Total	Cash And Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Common Stock	Accounts Payable	Non Currrent Assets Other	Other Current Assets	Good Will	Intangible Assets	Other Assets	Property Plant Equipment
Total Assets		0.55	0.83	-0.68	-0.78	0.89	-0.36	0.86	0.62	0.68	0.92	0.93	0.93	0.7	0.76	0.89	0.36	0.87	-0.35	0.69	0.21	0.91	0.89	0.94	0.89	0.77
Short Long Term Debt Total	0.55		0.84	0.2	-0.86	0.17	-0.42	0.83	0.86	0.83	0.27	0.76	0.27	0.83	0.84	0.17	0.71	0.66	-0.4	0.81	-0.21	0.5	0.82	0.78	0.22	0.79
Total Current Liabilities	0.83	0.84		-0.25	-0.93	0.56	-0.4	0.94	0.84	0.82	0.63	0.93	0.61	0.82	0.86	0.56	0.58	0.82	-0.38	0.92	-0.14	0.72	0.96	0.92	0.6	0.84
Net Debt	-0.68	0.2	-0.25		0.17	-0.93	0.16	-0.31	0.05	0.03	-0.89	-0.44	-0.86	0.0	-0.07	-0.93	0.26	-0.47	0.17	-0.07	-0.57	-0.65	-0.33	-0.43	-0.82	-0.15
Retained Earnings	-0.78	-0.86	-0.93	0.17		-0.48	0.3	-0.96	-0.84	-0.83	-0.56	-0.88	-0.55	-0.83	-0.86	-0.48	-0.63	-0.88	0.28	-0.82	0.13	-0.71	-0.92	-0.89	-0.49	-0.78
Cash	0.89	0.17	0.56	-0.93	-0.48		-0.29	0.61	0.29	0.28	0.99	0.72	0.96	0.31	0.38	1.0	0.03	0.71	-0.29	0.38	0.51	0.85	0.64	0.73	0.9	0.45
Common Stock Total Equity	-0.36	-0.42	-0.4	0.16	0.3	-0.29		-0.49	-0.03	-0.23	-0.33	-0.47	-0.41	-0.24	-0.27	-0.3	0.23	-0.36	1.0	-0.35	-0.15	-0.28	-0.42	-0.44	-0.2	-0.26
Common Stock Shares Outstanding	0.86	0.83	0.94	-0.31	-0.96	0.61	-0.49		0.77	0.78	0.68	0.93	0.68	0.78	0.83	0.62	0.51	0.89	-0.48	0.82	0.0	0.76	0.95	0.94	0.58	0.78
Total Liab	0.62	0.86	0.84	0.05	-0.84	0.29	-0.03	0.77		0.82	0.36	0.74	0.29	0.82	0.84	0.28	0.93	0.66	-0.01	0.81	-0.19	0.6	0.81	0.78	0.37	0.8
Property Plant And Equipment Gross	0.68	0.83	0.82	0.03	-0.83	0.28	-0.23	0.78	0.82		0.36	0.76	0.43	1.0	0.99	0.28	0.67	0.66	-0.21	0.84	-0.43	0.54	0.83	0.77	0.46	0.92
Total Current Assets	0.92	0.27	0.63	-0.89	-0.56	0.99	-0.33	0.68	0.36	0.36		0.78	0.97	0.39	0.46	0.99	0.11	0.79	-0.33	0.44	0.48	0.9	0.7	0.79	0.91	0.51
Other Current Liab	0.93	0.76	0.93	-0.44	-0.88	0.72	-0.47	0.93	0.74	0.76	0.78		0.78	0.77	0.82	0.72	0.47	0.88	-0.46	0.8	0.13	0.89	0.96	0.97	0.73	0.82
Total Stockholder Equity	0.93	0.27	0.61	-0.86	-0.55	0.96	-0.41	0.68	0.29	0.43	0.97	0.78		0.46	0.52	0.96	0.02	0.78	-0.41	0.43	0.39	0.86	0.7	0.78	0.92	0.56
Property Plant And Equipment Net	0.7	0.83	0.82	0.0	-0.83	0.31	-0.24	0.78	0.82	1.0	0.39	0.77	0.46		1.0	0.3	0.68	0.68	-0.21	0.81	-0.38	0.57	0.83	0.79	0.49	0.93
Non Current Assets Total	0.76	0.84	0.86	-0.07	-0.86	0.38	-0.27	0.83	0.84	0.99	0.46	0.82	0.52	1.0		0.38	0.67	0.73	-0.25	0.83	-0.3	0.63	0.87	0.84	0.54	0.94
Cash And Short Term Investments	0.89	0.17	0.56	-0.93	-0.48	1.0	-0.3	0.62	0.28	0.28	0.99	0.72	0.96	0.3	0.38		0.02	0.71	-0.3	0.38	0.5	0.84	0.64	0.72	0.9	0.44
Non Current Liabilities Total	0.36	0.71	0.58	0.26	-0.63	0.03	0.23	0.51	0.93	0.67	0.11	0.47	0.02	0.68	0.67	0.02		0.43	0.25	0.58	-0.2	0.4	0.56	0.53	0.14	0.63
Other Stockholder Equity	0.87	0.66	0.82	-0.47	-0.88	0.71	-0.36	0.89	0.66	0.66	0.79	0.88	0.78	0.68	0.73	0.71	0.43		-0.34	0.63	0.17	0.87	0.85	0.89	0.7	0.7
Common Stock	-0.35	-0.4	-0.38	0.17	0.28	-0.29	1.0	-0.48	-0.01	-0.21	-0.33	-0.46	-0.41	-0.21	-0.25	-0.3	0.25	-0.34		-0.32	-0.18	-0.28	-0.4	-0.42	-0.19	-0.24
Accounts Payable	0.69	0.81	0.92	-0.07	-0.82	0.38	-0.35	0.82	0.81	0.84	0.44	0.8	0.43	0.81	0.83	0.38	0.58	0.63	-0.32		-0.33	0.52	0.89	0.81	0.46	0.82
Non Currrent Assets Other	0.21	-0.21	-0.14	-0.57	0.13	0.51	-0.15	0.0	-0.19	-0.43	0.48	0.13	0.39	-0.38	-0.3	0.5	-0.2	0.17	-0.18	-0.33		0.41	0.0	0.15	0.25	-0.23
Other Current Assets	0.91	0.5	0.72	-0.65	-0.71	0.85	-0.28	0.76	0.6	0.54	0.9	0.89	0.86	0.57	0.63	0.84	0.4	0.87	-0.28	0.52	0.41		0.81	0.88	0.82	0.63
Good Will	0.89	0.82	0.96	-0.33	-0.92	0.64	-0.42	0.95	0.81	0.83	0.7	0.96	0.7	0.83	0.87	0.64	0.56	0.85	-0.4	0.89	0.0	0.81		0.98	0.63	0.82
Intangible Assets	0.94	0.78	0.92	-0.43	-0.89	0.73	-0.44	0.94	0.78	0.77	0.79	0.97	0.78	0.79	0.84	0.72	0.53	0.89	-0.42	0.81	0.15	0.88	0.98		0.71	0.81
Other Assets	0.89	0.22	0.6	-0.82	-0.49	0.9	-0.2	0.58	0.37	0.46	0.91	0.73	0.92	0.49	0.54	0.9	0.14	0.7	-0.19	0.46	0.25	0.82	0.63	0.71		0.66
Property Plant Equipment	0.77	0.79	0.84	-0.15	-0.78	0.45	-0.26	0.78	0.8	0.92	0.51	0.82	0.56	0.93	0.94	0.44	0.63	0.7	-0.24	0.82	-0.23	0.63	0.82	0.81	0.66

Click cells to compare fundamentals

Cytosorbents Crp Account Relationship Matchups

Cytosorbents Crp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.4M	90.0M	89.5M	63.2M	53.3M	55.9M
Short Long Term Debt Total	16.1M	1.0M	13.8M	18.3M	18.3M	19.2M
Total Current Liabilities	9.9M	10.2M	13.7M	9.7M	14.5M	15.3M
Net Debt	3.9M	(70.4M)	(38.3M)	(3.9M)	4.2M	4.4M
Retained Earnings	(188.8M)	(196.6M)	(221.2M)	(254.0M)	(282.5M)	(268.4M)
Cash	12.2M	71.4M	52.1M	22.1M	14.1M	13.2M
Common Stock Total Equity	32.6K	43.2K	43.5K	43.6K	39.3K	51.6K
Common Stock Shares Outstanding	32.3M	38.8M	43.4M	43.6M	44.7M	46.9M
Liabilities And Stockholders Equity	27.4M	90.0M	89.5M	63.2M	53.3M	55.9M
Total Liab	24.0M	10.7M	26.9M	27.9M	30.0M	31.5M
Property Plant And Equipment Gross	3.0M	3.1M	18.6M	23.3M	25.2M	26.4M
Total Current Assets	20.9M	82.5M	64.3M	33.8M	25.7M	17.6M
Accumulated Other Comprehensive Income	526.0K	(1.7M)	525.6K	2.3M	529.3K	555.8K
Other Current Liab	5.6M	6.8M	8.2M	6.3M	6.5M	6.8M
Total Stockholder Equity	3.4M	79.2M	62.6M	35.4M	23.3M	12.9M
Property Plant And Equipment Net	3.0M	3.1M	18.6M	23.3M	22.1M	23.2M
Non Current Assets Total	6.5M	7.5M	25.2M	29.5M	27.6M	28.9M
Cash And Short Term Investments	12.2M	71.4M	52.1M	22.1M	14.1M	14.1M
Non Current Liabilities Total	14.0M	582K	13.3M	18.1M	15.4M	16.2M
Other Stockholder Equity	191.6M	277.5M	283.2M	287.0M	305.2M	160.4M
Common Stock	32.6K	43.2K	43.5K	43.6K	54.2K	53.5K
Accounts Payable	2.0M	1.8M	2.8M	1.7M	3.8M	4.0M
Non Currrent Assets Other	3.5M	4.3M	1.9M	1.7M	(3.7M)	(3.5M)
Other Current Assets	2.1M	3.2M	2.9M	2.5M	1.8M	1.1M
Good Will	1.8M	2.6M	3.4M	4.2M	4.9M	5.1M
Intangible Assets	3.4M	4.2M	4.7M	4.4M	3.9M	4.1M
Other Assets	123.5K	5.4M	6.6M	1.7M	2.0M	1.1M
Property Plant Equipment	3.0M	2.1M	18.6M	10.7M	12.4M	13.0M
Long Term Debt	6.0M	9.3M	13.4M	5M	2.5M	3.8M
Net Receivables	4.5M	5.2M	4.5M	5.7M	6.1M	6.4M
Retained Earnings Total Equity	(188.8M)	(196.6M)	(221.2M)	(254.0M)	(228.6M)	(217.2M)
Inventory	2.1M	2.7M	4.8M	3.5M	3.7M	1.9M
Short Term Debt	2.1M	447K	571K	109K	2.9M	3.0M
Net Tangible Assets	56.6K	79.2M	62.6M	35.4M	40.7M	23.3M
Capital Surpluse	191.6M	277.5M	283.2M	287.0M	330.1M	215.6M
Short Long Term Debt	4M	666.7K	1.7M	2.5M	2.9M	1.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:

How To Invest In Cytosorbents

Details

Is Cytosorbents Stock a good investment?

Details

What is Cytosorbents Crp's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Cytosorbents Stock analysis

When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.

	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated

Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.64)

Revenue Per Share

0.814

Quarterly Revenue Growth

(0.08)

Return On Assets

(0.32)

Return On Equity

(0.97)

The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytosorbents Total Liab vs Current Deferred Revenue Analysis

Total Liab vs Current Deferred Revenue

Total Liab vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Total Liab

Current Deferred Revenue

Cytosorbents Crp fundamental ratios Correlations

Cytosorbents Crp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytosorbents Crp fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Cytosorbents Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Net	+ 1.0	Property Plant And Equipment Gross
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Non Current Assets Total	+ 0.99	Property Plant And Equipment Gross

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.93	Net Debt
Retained Earnings	- 0.93	Total Current Liabilities
Good Will	- 0.92	Retained Earnings
Intangible Assets	- 0.89	Retained Earnings